Fulminant multi-organ myositis as a rare immune-related adverse event of nivolumab–relatlimab (Opdualag) therapy in metastatic melanoma: a case report
Immune checkpoint inhibitors (ICIs) have transformed the management of metastatic melanoma, providing durable survival benefits in a subset of patients. However, their use is associated with immune-related adverse events (irAEs), which may be unpredict…